Bgm Group Ltd Revenue Growth Rates (BGM), Current and Historic Growth - CSIMarket
CSIMarket
 


Bgm Group Ltd  (BGM)
 

BGM's Revenue Growth by Quarter and Year

Bgm Group Ltd's Revenue results by quarter and year




BGM Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December 24.11
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 24.11

BGMs Annual Revenue
Bgm Group Ltd's Revenue in the fiscal year 2025 $ 37.92 millions
Bgm Group Ltd's Revenue in the fiscal year 2024 $ 24.11 millions
Bgm Group Ltd's Revenue in the fiscal year 2023 $ 45.75 millions
Bgm Group Ltd's Revenue in the fiscal year 2022 $ 64.86 millions
Bgm Group Ltd's Revenue in the fiscal year 2021 $ 57.10 millions




BGM Revenue fourth quarter 2024 Y/Y Growth Comment
Bgm Group Ltd reported drop in Revenue in the fourth quarter 2024 by -47.29% to $ 24.11 millions, from the same quarter in 2023.
This represents worst decline in recent Company history.

Looking into fourth quarter 2024 results within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Revenue growth. While Bgm Group Ltd' s Revenue meltdown of -47.29% ranks overall at the positon no. 3591 in the fourth quarter 2024.




BGM Revenue ( Y/Y Growth %) 2024
2023 2022 2021
4th Quarter December -47.29 % -29.46 % 13.59 % -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   -47.29 % -29.46 % 13.59 % -

Financial Statements
Bgm Group Ltd's fourth quarter 2024 Revenue $ 24.11 millions BGM's Income Statement
Bgm Group Ltd's fourth quarter 2023 Revenue $ 45.75 millions Quarterly BGM's Income Statement


BGM Revenue (Quarter on Quarter Growth %)

2024
2023 2022 2021
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   -47.29 % -29.46 % 13.59 % -




Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #195
Healthcare Sector #531
Overall #3591

Revenue Y/Y Growth Statistics
High Average Low
13.58 % -21.06 % -47.29 %
(Sep 30 2022)   (Sep 30 2024)
Revenue fourth quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #195
Healthcare Sector #531
Overall #3591
Revenue Y/Y Growth Statistics
High Average Low
13.58 % -21.06 % -47.29 %
(Sep 30 2022)   (Sep 30 2024)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Bgm Group Ltd's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BGM's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


BGM's IV. Quarter Q/Q Revenue Comment


Bgm Group Ltd's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2025)
12 Months Ending
(Sep 30 2024)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Sep 30 2022)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 37.92 $ 24.11 $ 45.75 $ 64.86 $ 57.10
Y / Y Revenue Growth (TTM) 57.25 % -47.29 % -29.46 % 13.58 % 14.12 %
Year on Year Revenue Growth Overall Ranking # 3497 # 0 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 57.25 % -47.29 % -29.46 % 13.58 % 14.12 %
Seq. Revenue Growth (TTM) Overall Ranking # 3359 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Bgm Group Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 57.25% year on year, to $ 38 millions if the fiscal year would have ended in Sep 30 2025.
Bgm Group Ltd's trailing twelve months Revenue growth was higher than company's average -47.29% and higher than -47.29% growth in Sep 30 2024.
The momentum is even more impressive from twelve months ended Sep 30 2024 exhibited at 57.25 % increase from $24.11 millions in the period from Sep 30 2024 to Sep 30 2021.

In the Healthcare sector 501 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3497.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 171
Healthcare Sector # 502
Overall # 3497

Revenue TTM Y/Y Growth Statistics
High Average Low
-47.29 %
-47.29 %
-47.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 171
Sector # 477
S&P 500 # 3359
Cumulative Revenue growth Comment
Bgm Group Ltd saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 57.25% year on year, to $ 38 millions if the fiscal year would have ended in Sep 30 2025.
Bgm Group Ltd's trailing twelve months Revenue growth was higher than company's average -47.29% and higher than -47.29% growth in Sep 30 2024.
The momentum is even more impressive from twelve months ended Sep 30 2024 exhibited at 57.25 % increase from $24.11 millions in the period from Sep 30 2024 to Sep 30 2021.

In the Healthcare sector 501 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3497.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 171
Healthcare Sector # 502
Overall # 3497

Revenue TTM Y/Y Growth Statistics
High Average Low
-47.29 %
-47.29 %
-47.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 171
Sector # 477
S&P 500 # 3359




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BGM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue meltdown for the quarter ending Sep 30 2024 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2024
Adapthealth Corp -0.19%$ -0.185 millions
Bioaffinity Technologies Inc -0.26%$ -0.260 millions
Organon and Co -0.38%$ -0.375 millions
Royalty Pharma Plc-0.41%$ -0.407 millions
Carlisle Companies Incorporated-0.41%$ -0.408 millions
Silo Pharma Inc-0.41%$ -0.409 millions
Shl Telemedicine Ltd-0.52%$ -0.519 millions
Cytek Biosciences Inc -0.59%$ -0.586 millions
Kronos Bio Inc -0.70%$ -0.700 millions
Koninklijke Philips Nv-0.81%$ -0.815 millions
Enhabit Inc -0.92%$ -0.921 millions
Charles River Laboratories International inc -1.08%$ -1.078 millions
Elanco Animal Health Incorporated-1.45%$ -1.449 millions
Illumina Inc -1.60%$ -1.604 millions
Perrigo Company Plc-1.62%$ -1.616 millions
Fonar Corporation-1.72%$ -1.717 millions
Quipt Home Medical Corp -1.90%$ -1.905 millions
Bio rad Laboratories Inc -1.91%$ -1.910 millions
Surmodics Inc -2.06%$ -2.062 millions
Avantor Inc -2.10%$ -2.101 millions
Petvivo Holdings Inc -2.11%$ -2.111 millions
Iridex Corp-2.15%$ -2.153 millions
Assertio Holdings inc -2.43%$ -2.431 millions
Apyx Medical Corp-2.58%$ -2.578 millions
Bioxcel Therapeutics Inc -2.66%$ -2.660 millions
Zynex inc -2.66%$ -2.665 millions
Nrc Health-2.88%$ -2.879 millions
Teladoc Health Inc -3.03%$ -3.033 millions
Orchestra Biomed Holdings Inc -3.44%$ -3.435 millions
Xenetic Biosciences Inc -3.45%$ -3.449 millions


About Bgm Group Ltd Revenue Growth Rates (BGM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Bgm Group Ltd (CIK 1779578).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-085247
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Bgm Group Ltd’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.